These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34699029)

  • 1. Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension.
    Ogbomo A; Tsang Y; Kariburyo F; Tsai WL; Panjabi S
    Pulm Ther; 2021 Dec; 7(2):575-590. PubMed ID: 34699029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
    Tsang Y; Singh R; Verma S; Panjabi S
    Rheumatol Ther; 2023 Jun; 10(3):741-756. PubMed ID: 36959524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
    Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
    J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
    Copher R; Cerulli A; Watkins A; Laura Monsalvo M
    J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy.
    Ruiz G; Yeaw J; Lickert CA; De AP; Wade RL; Pruett J; Drake W
    J Health Econ Outcomes Res; 2018; 5(2):206-219. PubMed ID: 35620777
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
    Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
    Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension.
    Studer S; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Pulm Ther; 2020 Jun; 6(1):79-92. PubMed ID: 32048240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012.
    Anand V; Roy SS; Archer SL; Weir EK; Garg SK; Duval S; Thenappan T
    JAMA Cardiol; 2016 Dec; 1(9):1021-1029. PubMed ID: 27851838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data.
    Gauthier-Loiselle M; Tsang Y; Lefebvre P; Agron P; Royer J; Bell Lynum KS; Bennett L; Panjabi S
    Curr Med Res Opin; 2022 Jun; 38(6):1019-1030. PubMed ID: 35243952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
    Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
    J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
    Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
    Pulm Ther; 2021 Jun; 7(1):203-219. PubMed ID: 33728597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database.
    Studer S; Hull M; Pruett J; Koep E; Tsang Y; Drake W
    Pulm Circ; 2019; 9(1):2045894018816294. PubMed ID: 30421652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.
    Burger CD; Long PK; Shah MR; McGoon MD; Miller DP; Romero AJ; Benton WW; Safford RE
    Chest; 2014 Nov; 146(5):1263-1273. PubMed ID: 24901386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection.
    Wyffels V; Kariburyo F; Gavart S; Fleischhackl R; Yuce H
    Adv Ther; 2020 Mar; 37(3):1203-1217. PubMed ID: 32026380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States.
    Pizzicato LN; Nadipelli VR; Governor S; Mao J; Lanes S; Butler J; Pepe RS; Phatak H; El-Kersh K
    Pulm Circ; 2022 Apr; 12(2):e12090. PubMed ID: 35795495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations - Analysis of the National Inpatient Sample Database.
    Chaturvedi A; Kanwar M; Chandrika P; Thenappan T; Raina A; Benza RL
    Int J Cardiol; 2020 Nov; 319():131-138. PubMed ID: 32603739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.